Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use (FALLA)
Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use
This is a prospective, single-arm, post marketing observational study in adult patients with active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with either infliximab or etanercept.
The aim of this post-marketing observational study is to obtain data on clinical outcomes, compliance and tolerability to determine the effectiveness of switching from infliximab or etanercept to adalimumab. In this cohort, the different treatment strategies are to be studied in the context of the routine clinical practice in the different participating places.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This is a prospective, single-arm, post marketing observational study in adult patients with active RA who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with either infliximab or etanercept.
The aim of this post-marketing observational study is to obtain data on clinical outcomes, compliance and tolerability to determine the effectiveness of switching from infliximab or etanercept to Adalimumab. In this cohort, the different treatment strategies are to be studied in the context of the routine clinical practice in the different participating places.
Study Objectives:
Primary objective:
To assess the effectiveness of the treatment with adalimumab in patients with rheumatoid arthritis (RA) that have failed or presented an incomplete response to current treatment with either infliximab or etanercept.
Secondary objective:
To evaluate the compliance and clinical tolerability with adalimumab
Investigational Plan and Selection of Study Population:
All patients belonging to any of the centres participating in the study that meet all the inclusion criteria and none of the exclusion criteria will be considered eligible.
Patients considered eligible for the study will have to give their consent for the use and/or disclose of the patient's personal and/or health data. Patient's consent will be obtained before his/her participation in the study and will be documented in an Informed Consent Form approved by an Ethics Committee.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Chihuahua, Mexico, 31000
- Site Reference ID/Investigator# 27882
-
Chihuahua, Mexico, 31200
- Site Reference ID/Investigator# 27883
-
Culiacán Sin., Mexico, 80000
- Site Reference ID/Investigator# 27884
-
Guadalajara, Jal., Mexico, 44320
- Site Reference ID/Investigator# 27888
-
Guadalajara, Jal., Mexico, 44650
- Site Reference ID/Investigator# 27886
-
Guadalajara, Jal., Mexico, 44670
- Site Reference ID/Investigator# 27887
-
Leon, Gto., Mexico, 37000
- Site Reference ID/Investigator# 25943
-
Mexico City, Mexico, 03100
- Site Reference ID/Investigator# 28059
-
Mexico City,, Mexico, 06700
- Site Reference ID/Investigator# 27885
-
Puebla, Pue., Mexico, 72000
- Site Reference ID/Investigator# 27890
-
Puebla, Pue., Mexico, 72570
- Site Reference ID/Investigator# 27889
-
Tuxtla Gutierrez, Mexico, 29000
- Site Reference ID/Investigator# 28057
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients ≥18 and <75 years of age that meet the American College of Rheumatology (ACR) criteria for RA.
Patients with active RA defined as:
- ≥3 tender joints and ≥3 swollen joints, or
- DAS 28 score >3.1
Patients who are discontinuing treatment with either infliximab or etanercept due to:
- Lack of efficacy, or
- Incomplete response.
- Patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab
- Those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.
Exclusion Criteria:
The following patients will not be included in the study:
- Patients who have active infections.
- Patients with latent TB. For this protocol, evidence of latent TB infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. Any suggested data on the clinical history or chest x-ray.
- Patients participating into another study or clinical trial
- Any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Non responders to other anti-TNF
Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers.
A 40 mg dose was administered every other week for 24 weeks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
DAS28 (Disease Activity Score in 28 Joints)
Tidsramme: Baseline and Weeks 8,16 and 24
|
The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from "very good" to "very bad").
Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (<= 2.6), Low Disease Activity (>2.6 to <=3.2), Moderate Disease Activity (>3.2 to <= 5.1) and High Disease Activity (>5.1).
The mean change in DAS 28 score from baseline to each visit is presented.
|
Baseline and Weeks 8,16 and 24
|
|
Tender Joint Count and Swollen Joint Count
Tidsramme: Baseline and Weeks 8,16 and 24
|
The treating physician was to clinically assess each participant at each study visit and report the number of tender and swollen joints.
The mean number of painful or swollen joints for participants evaluated at each time point are presented.
|
Baseline and Weeks 8,16 and 24
|
|
Severity of Pain in a 100mm Visual Analogue Scale (VAS 100mm)
Tidsramme: Baseline and Weeks 8,16 and 24
|
Participants assessed the severity of their pain using a 0 to 100 mm horizontal visual analogue scale (VAS).
The far left end indicated no pain (0 mm) and the far right meant the worst possible pain (100 mm).
Participants drew a vertical line on the horizontal scale to indicate their current level of pain at each visit.
|
Baseline and Weeks 8,16 and 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate the Compliance and Clinical Tolerability With Adalimumab
Tidsramme: Baseline to Week 24
|
To assess compliance, participants were asked at the Week 8 and Week 16 visits how many doses they had missed since their previous visit.
Adverse events were collected throughout the study, from the time the participant signed the informed consent form until 30 days or 5 half-lives after the last dose of study drug.
For additional information see the Reported Adverse Event section.
|
Baseline to Week 24
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Juan Pozos, MD, Abbott
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P10-604
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .